A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
Peter Nägele, Ben Julian A. Palanca, Britt M. Gott, Frank Brown, Linda Barnes, Thomas Nguyen, Willa Xiong, Naji C. Salloum, Gemma Espejo, Christina N. Lessov‐Schlaggar, Nisha Jain, Wayland W.L. Cheng, Helga Komen, Branden E. Yee, Jacob Bolzenius, Alvin M. Janski, Robert D. Gibbons, Charles F. Zorumski, Charles R. Conway
Abstract
< 0.001). These results suggest that 25% nitrous oxide has comparable efficacy to 50% nitrous oxide in improving TRMD but with a markedly lower rate of adverse effects.
Topics & Concepts
Nitrous oxideDepression (economics)Adverse effectTreatment-resistant depressionMedicineInhalationAnesthesiaMajor depressive disorderClinical trialInternal medicineAmygdalaMacroeconomicsEconomicsTreatment of Major DepressionTryptophan and brain disordersIntensive Care Unit Cognitive Disorders